Daniel Lasanow
Chairman bij Polypeptide Laboratories France SAS
Vermogen: 261 286 $ op 31-03-2024
Profiel
Daniel Lasanow currently works at Polypeptide Laboratories France SAS, as Chairman from 2017.
Mr. Lasanow also formerly worked at Lonza, Inc., as Production Director, NextPharma Technologies SA (Belgium), as Production Director from 2009 to 2011, UCB-Bioproducts SA, as Production Director, and PolyPeptide Group AG, as Director-Global Operations from 2016 to 2022.
Mr. Lasanow received his graduate degree from Université Catholique de Louvain.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
POLYPEPTIDE GROUP AG
0.02% | 31-12-2022 | 7 767 ( 0.02% ) | 261 286 $ | 31-03-2024 |
Actieve functies van Daniel Lasanow
Bedrijven | Functie | Begin |
---|---|---|
Polypeptide Laboratories France SAS
Polypeptide Laboratories France SAS Chemicals: SpecialtyProcess Industries Part of PolyPeptide Group AG, Polypeptide Laboratories France SAS is a contract manufacturer of organic peptides. The private company is based in Strasbourg, France. | Chairman | 10-04-2017 |
Eerdere bekende functies van Daniel Lasanow
Bedrijven | Functie | Einde |
---|---|---|
POLYPEPTIDE GROUP AG | Chief Operating Officer | 30-11-2022 |
NextPharma Technologies SA (Belgium) | Corporate Officer/Principal | 01-01-2011 |
UCB-Bioproducts SA
UCB-Bioproducts SA Miscellaneous Commercial ServicesCommercial Services UCB-Bioproducts is a Belgian based, international Contract Services Company, focusing on custom peptide and peptidomimetics (for pharmaceutical use) process development, regulatory services and manufacturing services along with strong support to customers' clinical trials. UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the lives of people. | Corporate Officer/Principal | - |
Lonza, Inc.
Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Corporate Officer/Principal | - |
Opleiding van Daniel Lasanow
Université Catholique de Louvain | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
POLYPEPTIDE GROUP AG | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Lonza, Inc.
Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Process Industries |
NextPharma Technologies SA (Belgium) | |
UCB-Bioproducts SA
UCB-Bioproducts SA Miscellaneous Commercial ServicesCommercial Services UCB-Bioproducts is a Belgian based, international Contract Services Company, focusing on custom peptide and peptidomimetics (for pharmaceutical use) process development, regulatory services and manufacturing services along with strong support to customers' clinical trials. UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the lives of people. | Commercial Services |
Polypeptide Laboratories France SAS
Polypeptide Laboratories France SAS Chemicals: SpecialtyProcess Industries Part of PolyPeptide Group AG, Polypeptide Laboratories France SAS is a contract manufacturer of organic peptides. The private company is based in Strasbourg, France. | Process Industries |